Verastem's $32M Series B to Fund Cancer Stem Cell Work
By Jennifer Boggs
Friday, July 15, 2011
Founded only last year to develop cancer drugs that work by attacking cancer stem cells, Verastem Inc. already has closed its second round on funding, bringing in $32 million in a Series B.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.